-
GTA 6 Release Date Confirmed for November 19; Troubleshooting Pre-load and Launch Errors
-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
Olenox October Bitcoin Production Climbs to Three-Month High as Uptime and Hashrate Advance
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Dermata Announces U.S. Trademark Registration for TOME(R)
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
Healthcare AI Shakeout: Health Systems Plan to Cut AI Vendors Nearly in Half by 2028, Black Book Finds
-
Sparta Capital Ltd. Announces Resumption of Trading
-
TrizCom PR Wins Fourth PRSA Dallas Best of Show Award; Founder Jo Trizila Receives Norm Teich Award
-
CORRECTION FROM SOURCE: Nixxy Announces 1-for-20 Reverse Stock Split
-
Olenox Secures Texas Pipeline Operating Permit, Clearing Path for Initial 4 MW Power Deployment
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
WHO pushes two Ebola treatments found to boost survival rates
The World Health Organization said Friday that two existing treatments dramatically reduced deaths from Ebola and should be given to people of all ages suffering from the often-fatal haemorrhagic disease.
Publishing its first-ever guidelines on which therapeutics to use against Ebola, the UN health agency strongly recommended using two monoclonal antibodies, mAb114, also known as Ansuvimab or Ebanga, and REGN-EB3, or Inmazeb.
Studies had showed that the two treatments significantly "reduced mortality," Janet Diaz, lead of the clinical management unit in the WHO's Health Emergencies programme, told reporters in Geneva.
Depending on the standard of care, she said they could save between 230 and 400 lives for every 1,000 people infected.
In its guidelines, the WHO recommended against using other therapeutics that have been tested for Ebola, including monoclonal antibody ZMapp and antiviral drug remdesivir.
Ebola is an often-fatal viral haemorrhagic fever that was first identified in central Africa in 1976. The disease was named after a river in the Democratic Republic of Congo, then known as Zaire.
The worst epidemic in West Africa between 2013 and 2016 killed more than 11,300 people. The DRC has had more than a dozen epidemics, the deadliest killing 2,280 people in 2020.
Case fatality rates for the disease, which spreads through bodily fluids and causes high fever, vomiting and bleeding, can be as high as 80-90 percent, depending on how quickly it is detected and treated.
The WHO said mAb114 and REGN-EB3 should be given swiftly to anyone who contracts the virus.
In a statement the health agency said that the two had "demonstrated clear benefits" and could be used for everyone infected by Ebola, including older people, pregnant and breastfeeding women, children and newborns.
"Patients should receive recommended neutralising monoclonal antibodies as soon as possible after laboratory confirmation of diagnosis," it said.
The WHO cautioned though that access to both the treatments remained "challenging, especially in resource-poor areas."
"WHO is ready to support countries, manufacturers and partners to improve access to these treatments, and to support national and global efforts to increase affordability," the UN health agency said.
Robert Fowler of the University of Toronto, who co-chaired the guideline development group, hailed how "advances in supportive care and therapeutics over the past decade have revolutionised the treatment of Ebola."
"Ebola virus disease used to be perceived as a near certain killer. However, that is no longer the case," he said in the statement.
Combined with proper support, the two recommended treatments mean "recovery for the vast majority of people," he said.
A.Ruiz--AT